Back to Search Start Over

Evolving Strategies for the Management of Hand--Foot Skin Reaction Associated with the Multitargeted Kinase Inhibitors Sorafenib and Sunitinib.

Evolving Strategies for the Management of Hand--Foot Skin Reaction Associated with the Multitargeted Kinase Inhibitors Sorafenib and Sunitinib.

Authors :
LACOUTURE, MARIO E.
SHENHONG WU
ROBERT, CAROLINE
ATKINS, MICHAEL B.
KONG, HEIDI H.
GUITART, JOAN
GARBE, CLAUS
HAUSCHILD, AXEL
PUZANOV, IGOR
ALEXANDRESCU, DORU T.
ANDERSON, ROGER T.
WOOD, LAURA
DUTCHER, JANICE P.
Source :
Oncologist; Sep2008, Vol. 13 Issue 9, p1001-1011, 11p, 1 Color Photograph, 3 Diagrams, 3 Charts
Publication Year :
2008

Abstract

The multitargeted kinase inhibitors (MKIs) sorafenib and sunitinib have shown benefit in patients with renal cell carcinoma, hepatocellular carcinoma (sorafenib), and gastrointestinal stromal tumor (sunitinib). Their efficacy in other malignancies is currently being investigated because of their broad range of activity. The effectiveness of these drugs is somewhat diminished by the development of a variety of toxicities, most notably hand-foot skin reaction (HFSR). Although HFSR does not appear to directly affect survival, it can impact quality of life and lead to MKI dose modification or interruption, potentially limiting the antitumor effect. Currently, no standard guidelines exist for the prevention and management of MKI-associated HFSR. To address this issue, an international, interdisciplinary panel of experts gathered in January 2008 to discuss and evaluate the best-practice management of these reactions. Based on these proceedings, recommendations for the management of HFSR have been provided to offer patients the best possible quality of life while taking these drugs and to optimize the patient benefit associated with MKI therapy. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
10837159
Volume :
13
Issue :
9
Database :
Complementary Index
Journal :
Oncologist
Publication Type :
Academic Journal
Accession number :
34754296
Full Text :
https://doi.org/10.1634/theoncologist.2008-0131